Clinical Trial Update: Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction [Phase 3]

View source ↗

Summary

Phase 3 study of vortioxetine 10 mg and 20 mg for major depressive disorder with sexual dysfunction has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Sexual Dysfunction

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Takeda | Conditions: Treatment Outcome | Phase 3 | Status: COMPLETED | Results posted: 2014-10-09